COVID-19 Vaccine and Human Health

Dear Colleagues,

COVID-19 has proven to be a serious threat to public health; our responses, however, have proven to have negative impacts on the vitality of the economies around the world. In the rush to forestall the spread of SARS-CoV-2, vaccine development was undertaken with breathtaking speed. As a result, vaccine uptake has been hampered. Valid concerns exist on health issues related to COVID-19 vaccination in some people. New technologies have been used and the translational science process was, in some cases, truncated (combined phases). The long-term safety of COVID-19 vaccines is not yet assessed. This has led to widespread concern over the safety and efficacy of COVID-19 vaccines. The independent evaluation and appraisal of published data are extremely useful approaches toward rational discourse on vaccine safety and efficacy claims. Given that past studies of respiratory virus vaccines had negative impacts on the health and viability of human and animal vaccine recipients (i.e., disease enhancement), it is imperative that the following issues be given full and due independent consideration:

• Tests of hypotheses of pathogenic priming and disease enhancement;
• Comparisons of health effects of whole virus vs. mRNA vaccines;
• Re-examinations of published results on COVID-19 safety and efficacy;
• Medical exposures (e.g., drugs, flu vaccines/thimerosal, aluminum) and risk of serious illness and death in COVID-19;
• Immunological predictors of COVID-19 vaccine adverse events and long-haul COVID-19;
• Co-morbid conditions and age-related risks of vaccine adverse outcomes;
• Individualized medicine: who should, and who should not, receive COVID-19 vaccines?;
• Appraisals of the design and execution of translational science around COVID-19 vaccine development;
• Analyses of morbidity and mortality from vaccine safety databases;
• Plausible mechanisms of action of vaccine injury in COVID-19;
• Long-haul COVID-19 and vaccination;
• Critical appraisals of the evidence of protection from infection, serious illness and transmission; 
• Critique of CDC's Recommendations for Vaccination of people who have had COVID-19;
• Insertional mutagenesis of COVID-19 vaccine mRNA into human genomes;
• Off-target effects of mRNA vaccines;
• Critical Appraisals of Animal Studies in COVID-19 vaccine development.

Dr. James Lyons-Weiler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.